MCL Clinical Trials

1230 trials from ClinicalTrials.gov. Recruiting trials shown first.

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

NCT04043845·PHASE1·Dana-Farber Cancer Institute

IbrutinibLY3214996

Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)

NCT04127916·Samsung Medical Center·40 enrolled

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

NCT04172246·PHASE1 / PHASE2·BeiGene·55 enrolled

Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

NCT03834688·PHASE2·PrECOG, LLC.·33 enrolled

VenetoclaxBendamustineRituximab

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

NCT04191187·PHASE2·H. Lee Moffitt Cancer Center and Research Institute·34 enrolled

FludarabineMelphalanTotal Body Irradiation

A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

NCT04036448·Celgene·28 enrolled

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

NCT04116437·PHASE2·BeiGene·96 enrolled

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

NCT03997968·PHASE1 / PHASE2·Cyteir Therapeutics, Inc.·169 enrolled

CYT-0851CYT-0851 in combination with gemcitabineCYT-0851 in combination with capecitabineCYT-0851 in combination with rituximab and bendamustine

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

NCT03579927·PHASE1 / PHASE2·M.D. Anderson Cancer Center

Autologous Hematopoietic Stem Cell TransplantationCarmustineCytarabineEtoposideFilgrastim+3 more

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

NCT04082936·PHASE1 / PHASE2·IGM Biosciences, Inc.·97 enrolled

Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

NCT03891355·PHASE2·Fondazione Italiana Linfomi - ETS·16 enrolled

CarfilzomibLenalidomideDexamethasone

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT04047797·PHASE2·M.D. Anderson Cancer Center·3 enrolled

IxazomibIxazomib CitrateRituximab

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

NCT04716075·PHASE2·Polish Lymphoma Research Group·29 enrolled

Acalabrutinib 2x100 MG Oral Capsule + alloSCT

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

NCT03232307·PHASE2·M.D. Anderson Cancer Center

DexamethasoneIbrutinibLenalidomideRituximab

Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma

NCT04061850·Samsung Medical Center·88 enrolled

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

NCT03190330·PHASE4·Johnson & Johnson Private Limited·75 enrolled

Ibrutinib 420 mgIbrutinib 560 mg

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

NCT03939182·PHASE1·Memorial Sloan Kettering Cancer Center·15 enrolled

AbexinostatIbrutinib

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

NCT03601819·PHASE1·University of Michigan Rogel Cancer Center·4 enrolled

A Disease Registry of Patients With Mantle Cell Lymphoma

NCT03816683·AstraZeneca·227 enrolled

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

NCT03740529·PHASE1 / PHASE2·Loxo Oncology, Inc.·803 enrolled

PirtobrutinibVenetoclaxRituximab

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

NCT03833180·PHASE1·VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·91 enrolled

Zilovertamab vedotin

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

NCT03877055·PHASE1 / PHASE2·Memorial Sloan Kettering Cancer Center·8 enrolled

CopanlisibIbrutinib

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

NCT03647124·Celgene·105 enrolled

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

NCT03886831·PHASE1·Prelude Therapeutics·232 enrolled

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

NCT03685344·PHASE1·ADC Therapeutics S.A.·13 enrolled

Loncastuximab Tesirine and Durvalumab

BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma

NCT03836768·PHASE1·Zhejiang DTRM Biopharma·20 enrolled

Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

NCT03219047·EARLY_PHASE1·M.D. Anderson Cancer Center·1 enrolled

Best PracticeIbrutinibPatient Derived XenograftPersonalized Medicine

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

NCT03684694·PHASE1 / PHASE2·ADC Therapeutics S.A.·136 enrolled

Loncastuximab TesirineIbrutinib

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

NCT03999697·PHASE1·PersonGen BioTherapeutics (Suzhou) Co., Ltd.·10 enrolled

Autologous chimeric antigen receptor T cell transfusing agent targeting CD22

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

NCT03623373·PHASE2·Washington University School of Medicine·13 enrolled

BendamustineRituximabAcalabrutinibCytarabineLeukapheresis+3 more

← PreviousPage 11 of 41Next →